Skip to main content
Top
Published in: Gastric Cancer 1/2024

25-11-2023 | Gastric Cancer | Original Article

Randomized controlled trial comparing the costs of gastric cancer screening systems between serological risk-based upper gastrointestinal endoscopy and the existing barium photofluorography: gastric cancer screening labeled by serum examination in place of aged gastric cancer organized screening systems (GALAPAGOS study)

Authors: Takuji Gotoda, Hideki Ishikawa, Chika Kusano, Sho Suzuki, Hirohide Ohnishi, Kentaro Sugano, Yutaka Matsuyama

Published in: Gastric Cancer | Issue 1/2024

Login to get access

Abstract

Background

Although the risk of gastric cancer can be stratified according to Helicobacter pylori (H. pylori) IgG antibody titer and pepsinogen levels (ABC classification), a population-based gastric cancer screening system combining serological tests and endoscopy has not been introduced. This study aimed to compare the total testing cost per participant between the ABC classification method and the existing protocol.

Methods

Using the minimization method with sex and age as allocation factors, 1206 participants were randomly assigned to the following two methods for a 5-year intervention: barium photofluorography as primary examination followed by detailed examination with upper gastrointestinal endoscopy (Ba-Endo) and risk-based upper gastrointestinal endoscopy by ABC classification (ABC-Endo). The primary endpoint was the total testing cost per participant over a 5-year period. The secondary endpoint was the expense required to detect one gastric cancer.

Results

The total testing cost per participant was 39,711 yen in Ba-Endo (604 participants) and 45,227 yen in ABC-Endo (602 participants), with the latter being significantly higher (p < 0.001). During the intervention period, gastric cancer was found in 11 and eight participants in Ba–Endo and ABC-Endo, respectively. The expenses required to detect one gastric cancer were 2,240,931 yen in Ba-Endo and 3,486,662 yen in ABC-Endo.

Conclusions

The testing cost per participant turned out to be higher in the ABC-Endo group than in the Ba-Endo group. This superiority trial, based on the hypothesis that the cost of testing is lower for ABC-Endo than for Ba-Endo, was rejected.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferly J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed Sung H, Ferly J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.CrossRefPubMed
2.
go back to reference Matsuda T, Ajiki W, Marugame T, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol. 2011;41:40–51.CrossRefPubMed Matsuda T, Ajiki W, Marugame T, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol. 2011;41:40–51.CrossRefPubMed
3.
go back to reference Oh CM, Won YJ, Jung KW, et al. Community of population-based regional cancer registries cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48:436–50.CrossRefPubMedPubMedCentral Oh CM, Won YJ, Jung KW, et al. Community of population-based regional cancer registries cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48:436–50.CrossRefPubMedPubMedCentral
4.
go back to reference Huang RJ, Koh H, Hwang JH, et al. A summary of the 2020 gastric cancer summit at Stanford university. Gastroenterology. 2020;159:1221–6.CrossRefPubMed Huang RJ, Koh H, Hwang JH, et al. A summary of the 2020 gastric cancer summit at Stanford university. Gastroenterology. 2020;159:1221–6.CrossRefPubMed
5.
go back to reference Suh M, Song S, Cho HN, et al. Trends in participation rates for the national cancer screening program in Korea, 2002–2012. Cancer Res Treat. 2017;49:798–806.CrossRefPubMed Suh M, Song S, Cho HN, et al. Trends in participation rates for the national cancer screening program in Korea, 2002–2012. Cancer Res Treat. 2017;49:798–806.CrossRefPubMed
6.
go back to reference Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017;152(1319–28): e7. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017;152(1319–28): e7.
7.
go back to reference Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38:259–67.CrossRefPubMed Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38:259–67.CrossRefPubMed
8.
go back to reference Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013;8: e79088.CrossRefPubMedPubMedCentral Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fukao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One. 2013;8: e79088.CrossRefPubMedPubMedCentral
9.
go back to reference Hamashima C. On behalf of the systematic review group and guideline development group for gastric cancer screening guidelines. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2018;48:673–83.CrossRefPubMed Hamashima C. On behalf of the systematic review group and guideline development group for gastric cancer screening guidelines. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2018;48:673–83.CrossRefPubMed
10.
go back to reference Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Bio Mark. 2010;25:207–12.CrossRef Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Bio Mark. 2010;25:207–12.CrossRef
11.
go back to reference Yoshida T, Kato J, Inoue I, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer. 2014;134:1445–57.CrossRefPubMed Yoshida T, Kato J, Inoue I, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer. 2014;134:1445–57.CrossRefPubMed
12.
go back to reference Gotoda T, Ishikawa H, Ohnishi H, et al. Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer. 2015;18:605–11.CrossRefPubMed Gotoda T, Ishikawa H, Ohnishi H, et al. Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy. Gastric Cancer. 2015;18:605–11.CrossRefPubMed
13.
go back to reference Matsuda T, Marugame T, Tamo K, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42:139–47.CrossRefPubMed Matsuda T, Marugame T, Tamo K, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42:139–47.CrossRefPubMed
14.
go back to reference Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One. 2014;9: e109783.CrossRefPubMedPubMedCentral Terasawa T, Nishida H, Kato K, et al. Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians: a systematic review and meta-analysis. PLoS One. 2014;9: e109783.CrossRefPubMedPubMedCentral
15.
go back to reference Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.CrossRefPubMedPubMedCentral Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–72.CrossRefPubMedPubMedCentral
16.
go back to reference Taniyama Y, Katanoda K, Charvat H, et al. Estimation of lifetime cumulative incidence and mortality risk of gastric cancer. Jpn J Clin Oncol. 2017;47:1097–102.CrossRefPubMedPubMedCentral Taniyama Y, Katanoda K, Charvat H, et al. Estimation of lifetime cumulative incidence and mortality risk of gastric cancer. Jpn J Clin Oncol. 2017;47:1097–102.CrossRefPubMedPubMedCentral
17.
go back to reference Li WQ, Qin XX, Li ZX, et al. Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: a population-based study. Endoscopy. 2022;54:848–58.CrossRefPubMed Li WQ, Qin XX, Li ZX, et al. Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: a population-based study. Endoscopy. 2022;54:848–58.CrossRefPubMed
18.
go back to reference Noh CK, Lee E, Lee GH, et al. Association of regular endoscopic screening with interval gastric cancer incidence in the national cancer screening program. J Clin Med. 2021;11:230.CrossRefPubMedPubMedCentral Noh CK, Lee E, Lee GH, et al. Association of regular endoscopic screening with interval gastric cancer incidence in the national cancer screening program. J Clin Med. 2021;11:230.CrossRefPubMedPubMedCentral
19.
go back to reference Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7:15491.CrossRefPubMedPubMedCentral Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7:15491.CrossRefPubMedPubMedCentral
20.
go back to reference Ueda J, Gosho M, Inui Y, et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter. 2014;19:105–10.CrossRefPubMed Ueda J, Gosho M, Inui Y, et al. Prevalence of Helicobacter pylori infection by birth year and geographic area in Japan. Helicobacter. 2014;19:105–10.CrossRefPubMed
21.
go back to reference Takahashi Y, Yamamich N, Kubota D, et al. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study. Gastric Cancer. 2022;25:481–9.CrossRefPubMed Takahashi Y, Yamamich N, Kubota D, et al. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study. Gastric Cancer. 2022;25:481–9.CrossRefPubMed
22.
go back to reference Kowada A. Cost-effectiveness of Helicobacter pylori test and eradication versus upper gastrointestinal series versus endoscopy for gastric cancer mortality and outcomes in high prevalence countries. Scand J Gastroenterol. 2019;54:685–9.CrossRefPubMed Kowada A. Cost-effectiveness of Helicobacter pylori test and eradication versus upper gastrointestinal series versus endoscopy for gastric cancer mortality and outcomes in high prevalence countries. Scand J Gastroenterol. 2019;54:685–9.CrossRefPubMed
23.
go back to reference Inoue M, Sawada N, Goto A, et al. High-negative anti-Helicobacter pylori IgG antibody titers and long-term risk of gastric cancer: Results from a large-scale population-based cohort study in Japan. Cancer Epidemiol Biomark Prev. 2020;29:420–6.CrossRef Inoue M, Sawada N, Goto A, et al. High-negative anti-Helicobacter pylori IgG antibody titers and long-term risk of gastric cancer: Results from a large-scale population-based cohort study in Japan. Cancer Epidemiol Biomark Prev. 2020;29:420–6.CrossRef
24.
go back to reference Hamashima C, Yoshimura K, Fukao A. A study protocol for expanding the screening interval of endoscopic screening for gastric cancer based on individual risks: prospective cohort study of gastric cancer screening. Ann Transl Med. 2020;8:1604.CrossRefPubMedPubMedCentral Hamashima C, Yoshimura K, Fukao A. A study protocol for expanding the screening interval of endoscopic screening for gastric cancer based on individual risks: prospective cohort study of gastric cancer screening. Ann Transl Med. 2020;8:1604.CrossRefPubMedPubMedCentral
25.
go back to reference Luu XQ, Lee K, Jun JK, et al. Effect of gastric cancer screening on long-term survival of gastric cancer patients: result of Korean national cancer screening program. J Gastroenterol. 2022;57:464–75.CrossRefPubMed Luu XQ, Lee K, Jun JK, et al. Effect of gastric cancer screening on long-term survival of gastric cancer patients: result of Korean national cancer screening program. J Gastroenterol. 2022;57:464–75.CrossRefPubMed
26.
go back to reference Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;14:15491.CrossRef Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;14:15491.CrossRef
27.
go back to reference Kowada A, Asaka M. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: a cost-effectiveness analysis. Helicobacter. 2021;26: e12837.CrossRefPubMedPubMedCentral Kowada A, Asaka M. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: a cost-effectiveness analysis. Helicobacter. 2021;26: e12837.CrossRefPubMedPubMedCentral
Metadata
Title
Randomized controlled trial comparing the costs of gastric cancer screening systems between serological risk-based upper gastrointestinal endoscopy and the existing barium photofluorography: gastric cancer screening labeled by serum examination in place of aged gastric cancer organized screening systems (GALAPAGOS study)
Authors
Takuji Gotoda
Hideki Ishikawa
Chika Kusano
Sho Suzuki
Hirohide Ohnishi
Kentaro Sugano
Yutaka Matsuyama
Publication date
25-11-2023
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 1/2024
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-023-01449-3

Other articles of this Issue 1/2024

Gastric Cancer 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.